Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Acute lymphoblasticleukemia (ALL) in infants diagnosed at less than 12 months of age is an aggressive malignancy with a poor prognosis. Rearrangements of the KMT2Agene ( KMT2A-r) are present in up to 80% of cases, with 5-year event-free survival (EFS) less than 40%.[1][1] Dose intensive